Advertisement
Advertisement
U.S. markets open in 8 hours 29 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Fresenius SE & Co. KGaA (FRE.DE)

XETRA - XETRA Delayed Price. Currency in EUR
Add to watchlist
21.66-0.08 (-0.37%)
At close: 05:42PM CEST
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close21.74
Open21.94
Bid21.58 x N/A
Ask21.60 x N/A
Day's Range21.47 - 22.18
52 Week Range20.98 - 42.50
Volume1,205,668
Avg. Volume1,537,081
Market Cap12.2B
Beta (5Y Monthly)1.10
PE Ratio (TTM)7.10
EPS (TTM)3.05
Earnings DateNov 01, 2022
Forward Dividend & Yield0.92 (4.23%)
Ex-Dividend DateMay 16, 2022
1y Target Est39.13
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for FRE.DE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Reuters

      FOCUS-Fresenius taps pre-dialysis kidney care as drugs promise treatment change

      The world’s largest dialysis company is seeking out kidney disease patients long before they need the most acute form of care as it plans for growth of new drugs that attack the condition’s causes early on. For decades, Germany's Fresenius Medical Care (FMC) has been the biggest player in the $50 billion U.S. market providing dialysis and related machines that help filter out blood toxins for people whose kidneys have failed to function. The company’s 17.6 billion euros ($17.6 billion) in annual revenue has been sustained for decades by high rates of obesity and diabetes, which contribute to kidney damage.

    • Reuters

      Fresenius SE CEO to quit after earnings outlook sours

      FRANKFURT (Reuters) -Fresenius SE said its long-serving Chief Executive Stephan Sturm would quit, to be replaced by the head of its drugs unit, after the diversified group's earnings were hit following the COVID pandemic and a surge in costs. Michael Sen, a former management board member of Siemens and finance chief of E.ON, who now runs hospital drugs division Kabi, will take the helm on Oct. 1, the company said on Friday. Stephan Sturm, finance chief since 2005 and CEO since 2016, would leave the company "on good terms", it said in a statement, without giving a reason for his departure.

    • Moody's

      Fresenius Finance Ireland II Plc -- Moody's affirms Fresenius SE's Baa3 rating; outlook stable

      Rating Action: Moody's affirms Fresenius SE's Baa3 rating; outlook stableGlobal Credit Research - 15 Aug 2022Frankfurt am Main, August 15, 2022 -- Moody's Investors Service ("Moody's") has today affirmed Fresenius SE & Co. KGaA's (FSE or the company) Baa3 long-term issuer rating. During the period of subdued operating performance, which will likely last until end of 2023, Moody's expects FSE will remain fully committed to its investment grade rating by prioritizing its public commitment to the 3-3.5x net leverage range over capital allocation to M&A and shareholders' distribution. The rating as of today is weakly positioned.

    Advertisement
    Advertisement